A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 96
- Population
- ALL · 55 Years
- Duration
- 2019-04-15 to 2024-12-18
- Intervention
- EPA+DHA; placebo
- Comparator
- Placebo Group
- Outcomes measured
- Intervention Effects on Plasma Levels of Lipid Mediator of Inflammation HEPE5 — 0, 4, 8 and 12 weeks; Intervention Effects on Plasma Levels of Lipid Mediator of Inflammation HEPE11 — 0, 4, 8 and 12 weeks; Intervention Effects on Plasma Levels of Lipid Mediator of Inflammation HEPE12 — 0, 4, 8 and 12 weeks; Intervention Effects on Plasma Levels of Lipid Mediator of Inflammation HEPE15 — 0, 4, 8 and 12 weeks; Intervention Effects on Plasma Levels of Lipid Mediator of Inflammation HEPE18 — 0, 4, 8 and 12 weeks; Comparison of Intervention and Control Groups in IL-1β Levels (Log pg/mL) — 0, 4, 8 and 12 weeks; Comparison of Intervention and Control Groups in IL-6 Levels (Log pg/mL) — 0, 4, 8 and 12 weeks; 1. Comparison of Intervention and Control Groups in TNF-α Levels (Log pg/mL) — 0, 4, 8 and 12 weeks; Comparison of Intervention and Control Groups in IFN-γ Levels (Log pg/mL) — 0, 4, 8 and 12 weeks; Intervention Effects on Polymorphonuclear Leukocyte (PMN) Activation (Log Cells/µL) — 0, 4, 8 and 12 weeks; Intervention Effects on Polymorphonuclear Leukocyte (PMN) - Derived Matrix Metalloproteinase-8 (MMP-8) Levels (Log pg/m…; Intervention Effects on Polymorphonuclear Leukocyte (PMN) - Derived Human Neutrophil Elastase (HNE, ELA2) Levels (Log p…; Comparison of Intervention vs. Control Groups in the Percent Change in Wound Area Relative to Baseline — 0, 4, 8 and 12…; Venous Insufficiency Epidemiological and Economic Study Quality Of Life/Symptom (VEINES-QOL/Sym) Questionnaire — 0, 12…; Venous Clinical Severity Score (VCSS) — 0, 4, 8, 12 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Omega-3 fatty acids · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.